The Ser460Pro mutation in recombinant protein S Heerlen does not affect its APC-cofactor and APC-independent anticoagulant activities

Summary

Protein S is a vitamin K-dependent plasma protein that functions as an APC-cofactor, but also exhibits anticoagulant activity in the absence of APC. The Heerlen polymorphism of protein S is characterized by a Ser460Pro substitution and lacks glycosylation at Asn458. It is associated with decreased protein S levels due to selective deficiency of free protein S Heerlen.To understand the lack of thrombotic complications associated with the protein S Heerlen mutation, we compared recombinant protein S Heerlen, wild type (wt) protein S and plasmaderived protein S. wt-Protein S and protein S Heerlen each bound 1:1 to C4BP with dissociation constants of 0.27 and 0.33 nM, respectively. Both wt-protein S and protein S Heerlen, either free or in complex with C4BP, were equally active as prothrombinase inhibitors in the absence of APC. All three protein S preparations stimulated APC-catalyzed inactivation of normal FVa, FVa Leiden and FVIIIa to the same extent. If extrapolated to plasma, it is not likely that the decreased free protein S levels in carriers of the protein S Heerlen mutation are compensated by an increased anticoagulant activity of protein S Heerlen-C4BP complexes. It is possible that an unrecognized plasma factor selectively enhances the anticoagulant activity of protein S Heerlen. If not, the reduction of free protein S levels in heterozygous protein S Heerlen-carriers combined with (low) normal total protein S levels apparently minimally affects the total anticoagulant activity of protein S (APC-cofactor and APC-independent activity) and hence is not associated with increased risk of venous thrombosis.

Keywords

Factor VIII - factor V - factor V Leiden - protein C/S pathway - protein function/activity

• References

• 1 Comp PC, Nixon RR, Cooper MR. et al. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74 (06) 2082-8.
• 2 Faioni E, Valsecchi C, Palla A. et al. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost 1997; 78 (05) 1343-6.
• 3 He X, Shen L, Malmborg A. et al. Binding site for C4b-binding protein in vitamin K-dependent protein S fully contained in carboxy-terminal laminin-G-type repeats. A study using recombinant factor IX-protein S chimeras and surface plasmon resonance. Biochemistry 1997; 36 (12) 3745-54.
• 4 Dahlbäck B. Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. Biochem J 1983; 209 (03) 847-56.
• 5 Walker FJ, Chavin SI, Fay PJ. Inactivation of factor VIII by activated protein C and protein S. Arch Biochem Biophys 1987; 252 (01) 322-8.
• 6 Koedam JA, Meijers JC, Sixma JJ. et al. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82 (04) 1236-43.
• 7 Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256 (21) 11128-31.
• 8 Rosing J, Hoekema L, Nicolaes GA. et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270 (46) 27852-8.
• 9 Norstrom EA, Steen M, Tran S, Dahlback B. Importance of protein S and phospholipid for activated protein C-mediated cleavages in factor Va. J Biol Chem 2003; 278 (27) 24904-11.
• 10 Deguchi H, Fernandez JA, Griffin JH. Neutral glycosphingolipid-dependent inactivation of coagulation factor Va by activated protein C and protein S. J Biol Chem 2002; 277 (11) 8861-5.
• 11 Norstrom E, Thorelli E, Dahlback B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood 2002; 100 (02) 524-30.
• 12 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269 (29) 18735-8.
• 13 Varadi K, Rosing J, Tans G. et al. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost 1996; 76 (02) 208-14.
• 14 van de Poel RH, Meijers JC, Bouma BN. C4bbinding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein Cmediated inactivation of factor VIIIa. Thromb Haemost 2001; 85 (05) 761-5.
• 15 Heeb MJ, Mesters RM, Tans G. et al. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268 (04) 2872-7.
• 16 Hackeng TM, van’t Veer C, Meijers JC. et al. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269 (33) 21051-8.
• 17 Hackeng TM, Hessing M, van’t Veer C. et al. Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. J Biol Chem 1993; 268 (06) 3993-4000.
• 18 Heeb MJ, Rosing J, Bakker HM. et al. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91 (07) 2728-32.
• 19 Heeb MJ, Kojima Y, Rosing J. et al. C-terminal residues 621-635 of protein S are essential for binding to factor Va. J Biol Chem 1999; 274 (51) 36187-92.
• 20 van Wijnen M, Stam JG, van’t Veer C. et al. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost 1996; 76 (03) 397-403.
• 21 Sere KM, Janssen MP, Willems GM. et al. Purified protein S contains multimeric forms with increased APC-independent anticoagulant activity. Biochemistry 2001; 40 (30) 8852-60.
• 22 Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986; 261 (26) 12022-7.
• 23 Bertina R, Ploos Hvan Amstel, van Wijngaarden A. et al. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood 1990; 76 (03) 538-48.
• 24 Duchemin J, Gandrille S, Borgel D. et al. The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. Blood 1995; 86 (09) 3436-43.
• 25 Espinosa-Parrilla Y, Morell M, Souto JC. et al. Absence of linkage between type III protein S deficiency and the PROS1 and C4BP genes in families carrying the protein S Heerlen allele. Blood 1997; 89 (08) 2799-806.
• 26 Espinosa-Parrilla Y, Navarro G, Morell M. et al. Homozygosity for the protein S Heerlen allele is associated with type I PS deficiency in a thrombophilic pedigree with multiple risk factors. Thromb Haemost 2000; 83 (01) 102-6.
• 27 Borgel D, Duchemin J, Alhenc-Gelas M. et al. Molecular basis for protein S hereditary deficiency: genetic defects observed in 118 patients with type I and type IIa deficiencies. The French Network on Molecular Abnormalities Responsible for Protein C and Protein S Deficiencies. J Lab Clin Med 1996; 128 (02) 218-27.
• 28 Morboeuf O, Borgel D, Aiach M. et al. Expression and characterization of recombinant protein S with the Ser 460 Pro mutation. Thromb Res 2000; 100 (01) 81-8.
• 29 Giri TK, Yamazaki T, Sala N. et al. Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. Blood 2000; 96 (02) 523-31.
• 30 Lu D, Xie R, Rydzewski A. et al. The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Thromb Haemost 1997; 77 (06) 1156-63.
• 31 Giri TK, Linse S, Garcia Pde Frutos. et al. Structural requirements of anticoagulant protein S for its binding to the complement regulator C4b-binding protein. J Biol Chem 2002; 277 (17) 15099-106.
• 32 Bertina R. In: XVI congress of the ISTH. 1997. Florence, Italy: 1997.
• 33 Bakker HM, Tans G, Janssen-Claessen T. et al. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem 1992; 208 (01) 171-8.
• 34 Sarkar G, Sommer SS. The “megaprimer” method of site-directed mutagenesis. Biotechniques 1990; 08 (04) 404-7.
• 35 Nicolaes GA, Tans G, Thomassen MC. et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270 (36) 21158-66.
• 36 Giri TK, Hillarp A, Hardig Y. et al. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost 1998; 79 (04) 767-72.
• 37 Horn IR, van den Berg BMM, van der Meijden PZ. et al. Molecular Analysis of Ligand Binding to the Second Cluster of Complement-type Repeats of the Low Density Lipoprotein Receptor-related Protein. evidence for an allosteric component in receptorassociated protein-mediated inhibition of ligand binding. J Biol Chem 1997; 272 (21) 13608-13.
• 38 Morboeuf O, Aiach M, Gandrille S. Lack of sequence variations in the C4b-BP beta-chain in patients with type III protein S deficiency bearing the Ser 460 to Pro mutation: description of two new intragenic isomorphisms in the C4b-BP beta-chain gene (C4BPB). Br J Haematol 1998; 101 (01) 10-5.
• 39 Koenen RR, Tans G, van Oerle R. et al. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood 2003; 102 (05) 1686-92.
• 40 Simmonds R, Zöller B, Ireland H. et al. Genetic and phenotypic analysis of a large (122-Member) Protein S-Deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes. Blood 1997; 89 (12) 4364-70.
• 41 Almasy L, Soria JM, Souto JC. et al. A quantitative trait locus influencing free plasma protein S levels on human chromosome 1q: results from the Genetic Analysis of Idiopathic Thrombophilia (GAIT) project. Arterioscler Thromb Vasc Biol 2003; 23 (03) 508-11.